Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Ruthenium complexes can target determinants of tumour malignancy Bergamo A; Sava GDalton Trans 2007[Apr]; ä (13): 1267-72Metastases are more decisive for tumour prognosis than primary lesions, because of their multiple locations, low accessibility to surgery and/or radiotherapy, and generally poor responsiveness to chemotherapy. The metastasis should therefore be the primary target for drug therapy. Among ruthenium complexes, NAMI-A is a leading compound that shows selective effects for solid tumour metastases related to a mechanism of action involving the inhibition of the processes of tumour invasiveness. NAMI-A opens an avenue to new perspectives in cancer chemotherapy. This includes novel compounds directed at targets selectively expressed by tumour metastases, thus reducing the typical side effects of the current metal-based drugs that are active via their unselective DNA interaction.|*Drug Design[MESH]|Animals[MESH]|Antineoplastic Agents/*chemistry/therapeutic use[MESH]|Dimethyl Sulfoxide/*analogs & derivatives/chemistry/therapeutic use[MESH]|Humans[MESH]|Mice[MESH]|Molecular Structure[MESH]|Neoplasm Metastasis/*drug therapy[MESH]|Organometallic Compounds/*chemistry/therapeutic use[MESH]|Ruthenium Compounds[MESH]|Ruthenium/*therapeutic use[MESH] |
